Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2019-01-07 Investor Presentation
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Updates
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Update on Innovative R&D Capabilities and Pipeline Overview' from Glenmark Pharmaceuticals dated January 2019. It includes extensive information about the company's R&D infrastructure, leadership teams, clinical development, and pipeline assets. The content is structured as a presentation with slides, disclaimers, and agenda points, focusing on strategic and operational updates rather than financial results or regulatory filings. There is no indication that this is an earnings release, annual report, or regulatory filing. The document is clearly a presentation intended for investors or stakeholders to provide an update on R&D and pipeline progress. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2019-01-07 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about the completion of the transfer of the company's Active Pharmaceuticals Ingredient (API) business to a wholly owned subsidiary. It references a previous intimation and requests the exchanges to take note of the transfer. The document is short (1661 characters), contains no financial data or detailed report content, and serves as an official notification of a corporate action. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not qualify as a full report, financial supplement, or other specific filing types.
2019-01-01 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Glenmark Pharmaceuticals' entry into the branded dermatology segment in the United States. It is addressed to stock exchanges and includes a media release about a business development event (acquisition of branded dermatology products and strategic expansion). There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a strategic business update, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. Therefore, the most appropriate classification is a Capital/Financing Update (CAP), as it relates to business expansion and acquisition activities impacting the company's capital and operations.
2018-12-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific drug product. It is addressed to stock exchanges and includes a media release for public record. The content is a corporate announcement about regulatory approval and product pipeline status, not a financial report, earnings release, or management discussion. The document length is 4051 characters, which is relatively short and consistent with a press release or announcement rather than a detailed report. There is no financial data, no discussion of financial results, no voting results, no board changes, no legal proceedings, or other report types. Therefore, the document best fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements and compliance-related disclosures that do not fit other categories.
2018-12-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing new pharmacokinetic data on GBR 1302 presented at a medical congress. It is a media release intended for immediate dissemination and does not contain detailed financial data, regulatory filings, or comprehensive reports. It is not an earnings release or financial report but rather a corporate announcement about clinical trial data. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories, which is Regulatory Filings (RNS). The document length is 6292 characters, which is consistent with a press release rather than a full report.
2018-12-17 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval for a specific product. It is addressed to stock exchanges and includes a media release. There is no detailed financial data, no regulatory filing form, no financial report, or management discussion. The document is an announcement of a corporate event (FDA approval) rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and corporate news that does not fit other specific categories.
2018-12-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.